SENP6 and diffuse large B-cell lymphoma: Tumors from DLBCL patients with primary refractory disease or early relapse were enriched in the SENP6lowgroup (P = 0.0211, Fig. 3e), indicating that low SENP6 levels were associated with inferior prognosis.